N/A N=50 Pulmonary Artery Repair With Covered Stents
Pulmonary Stenosis · Pulmonary Regurgitation · Tetralogy of Fallot
Primary: Successful Repair of Conduit Disruption — 48 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=81 COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV
Pulmonary Valve Insufficiency · Pulmonary Regurgitation · Dysfunctional RVOT Conduit
Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 4 N=20 Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis
Aortic Stenosis
Primary: Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort. — -25 percent change
Phase 2 N=3 Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)
Aortic Valve Stenosis
Primary: Total Work Performed During a Maximal-effort Exercise Test
N/A N=26 COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement
Pulmonary Valve Insufficiency · Pulmonary Valve Degeneration · Congenital Pulmonary Valve Abnormality
Primary: Percentage of Subject's With Freedom From Device or Procedure Related Death and/or Reoperation at 1-year Post-implant. — 100.0 percentage of subjects
Phase 1 N=21 Sildenafil in Single Ventricle Patients
Heart Disease
Primary: Maximum Sildenafil Plasma Concentration — 181; 515; 545; 202 ng/mL
N/A N=16 Pressure Variability Study
Heart Failure
Primary: Mean Change in Pulmonary Artery Pressure (PAP) Due to Change in Posture — 27.7 mmHg — p=0.429
N/A N=112 Cutting Balloon Study
Pulmonary Artery Stenosis
Primary: Acute Change in Minimum Lumen Diameter Immediately Post-intervention — 85.1; 52.4 percentage change
Phase 4 N=5 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
N/A N=1,000 Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study
Atrial Septal Defect
Primary: Percent of Subjects With Two-year Device-related Hemodynamic Compromise — 0.65 percentage of participants
N/A N=30 PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
Phase 2 N=50 Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis
Pulmonary Veno Occlusive Disease
Primary: Number of Patients With Survival at 48 Weeks — 42 Participants
Phase 2 N=10 Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
Pulmonary Arterial Hypertension
Primary: Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and…
N/A N=90 Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
Eisenmenger Syndrome
Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants
N/A N=15 Simple Non-invasive Breathing Device to Improve Pulmonary Flow Pusatility in Single Ventricle Post Fontan
Single-ventricle
Primary: Change in Pulmonary Pulsatility Index — 51.6; 57.6 Ratio — p=0.1
N/A N=103 Assessmet of Patients With PAH Right Ventricular Volume
Pulmonary Arterial Hypertension
Primary: Observed Mean (Std Err) for % Difference Between VMS and MRI. — 4.80; 1.76; 2.03 Percent difference
N/A N=10 Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
Phase 2 N=48 Inhaled Nitrite in Subjects With Pulmonary Hypertension
Pulmonary Hypertension · Heart Failure, Diastolic
Primary: Change in Pulmonary Vascular Resistance (PVR) — 0.77; 0.40; -0.39 Woods units — p=0.002
Phase 2 N=16 Ambrisentan in Single Ventricle
Hypoplastic Left Heart Syndrome · Hypoplastic Right-sided Heart Complex
Primary: Area Under the Curve for Ambrisentan Plasma Concentration — 7871.46 ng*hr/mL
Phase 4 N=28 The Effects of Ambrisentan on Exercise Capacity in Fontan Patients
Single Ventricle Fontan Palliation
Primary: Change in VO2 Max — 1.33; 0.745 Change in ml/kg min
Phase 2 N=21 11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
Pulmonary Hypertension
Primary: Changes in RV Function — 7.56 percentage
N/A N=140 CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Pulmonary Valve Stenosis · Pulmonary Valve Insufficiency · Aortic Valve Stenosis
Primary: Hemodynamic Performance — 22.2; 13.5; 21.2; 21.9 mmHg
N/A N=555 Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network
Heart Defects, Congenital
Primary: Proportion of Patients Who Died or Received a Heart Transplant — 100; 72 Participants — p=0.013
Phase 4 N=14 Exercise Pulmonary Transit Time
Heart Failure, Diastolic
Primary: Pulmonary Transit Time — 2.5 seconds
Phase 2 N=82 Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants
Phase 4 N=30 Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
Pulmonary Hypertension
Primary: Observed the Change of Pulmonary Artery Systolic Pressure (PASP) Measured by Millimeters of Mercury (mm hg) Within Certain Time Periods. This is Per Sequence and Not a…
Phase 2 N=14 Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
Cystic Fibrosis
Primary: 6 Minute Walk Distance — 25.2; 0.75 meters
N/A N=125 Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs
Atrial Septal Defect
Primary: Number of Subjects With 6-Month Closure Success — 112 Participants — p=<0.0001
N/A N=50 Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography
Aortic Stenosis
Primary: Aortic Stenosis Acceleration Index Compared to Aortic Stenosis Severity — 21; 8; 1; 6 participants